课题基金 / 基金详情

COMPARISON OF THE CHROMOGENIC AND ONE-STAGE ASSAYS FOR FACTOR IX

COMPARISON OF THE CHROMOGENIC AND ONE-STAGE ASSAYS FOR FACTOR IX
因子 IX 显色法和一阶段法的比较
批准号:
3804918
负责人:
W FRICKE
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

W FRICKE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The one-stage clotting assay is the basis for the most widely used method for determining factor IX activity. It is based on the correction of the clotting time of fIX deficient plasma by the addition of fIX. Recently, a new assay for fIX has been developed that assay involves the addition of fIX to a preparation of fXIa and fX. The amount of fIX added can be determined from the rate of cleavage of a chromogenic substrate by factor Xa. We have undertaken a formal comparison of the clotting and chromogenic assays for determining potency of factor IX concentrates. Multiple comparisons of the assays using CBER's current fIX standard, FN2 versus the current WHO standard, 84/618, demonstrated equivalence of the two methods. The value of FN2 by clotting assay was 9.3 and 9.1 for the chromogenic assay. Comparisons of multiple lots of factor IX concentrates submitted to CBER for testing indicated significant disagreement between the methods for some concentrates. This disagreement could be somewhat reduced when the chromogenic assay was read kinetically rather than using the endpoint method. Further comparative studies are in progress.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
EPITOPE MAPPING OF ANTIBODIES TO VON WILLEBRAND FACTOR
ACTIVATION OF FVIII BY FXA AND INHIBITION BY TISSUE FACTOR PATHWAY INHIBITOR
EPITOPE MAPPING OF ANTIBODIES TO FACTOR VIII
EPITOPE MAPPING OF FACTOR VIII AND VON WILLEBRAND FACTOR
  • 批准号:
    3770445
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    W FRICKE
  • 依托单位:
    --
海外基金